bioRxivCancer BiologyPreprint
High-Speed AFM Reveals IDR-Mediated Structural Plasticity of EML4-ALK Modulated by ALK Inhibitors
Xujun HaniD, Noriyuki KoderaiD, Neval Yilmaz, Katsuya SakaiiD, Sachiko Arai, Borui Li, Ryu Imamura, Dominic Chih‐Cheng VooniD, Koji FukudaiD, Shigeki NanjoiD, Holger FlechsigiD, Hiroyuki ManoiD, Kunio MatsumotoiD, Seiji YanoiD
Abstract
EML4-ALK is a key oncogenic driver in lung cancer, but variant-specific chemoresistance limits the efficacy of current ALK inhibitors. Because the N-terminus contains an intrinsically disordered region (IDR), how ALK inhibitors affect the structure and dynamics of full-length EML4-ALK remains unclear. Here, using high-speed atomic force microscopy (HS-AFM), we visualize the overall structures of three full-length EML4-ALK variants (v1, v3, and v5) at the single-molecule level. We identified a transient globular subdomain (residues 191-217) within the v3 IDR that contributes to distinct oligomerization patterns. Notably, ALK inhibitors compact the IDR subdomain and reduce oligomerization, whereas this effect is abolished by the resistance mutation ALKG1202R, suggesting that ALK inhibitors not only affect kinase activity but also modulate IDR dynamics. Our findings shed new light on the structural regulation of EML4-ALK and provide a foundation for developing next-generation targeted therapies that account for IDR-driven molecular behavior. TeaserHigh-speed AFM revealed the full-length EML4-ALK structures and their IDR-mediated plasticity caused by ALK kinase inhibitors
- organism: human
- assay: imaging
- research focus: protein folding & dynamics
- approach: microscopy & imaging analysis
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Phase-separation of EML4-ALK variant 3 is dependent upon an active ALK conformation
J. Sampson, M. Richards, … R. Bayliss·bioRxiv·Jun 11, 2020
- EML4-ALK V3 drives cell migration through NEK9 and NEK7 kinases in non-small-cell lung cancer
L. O'Regan, G. Barone, … A. M. Fry·bioRxiv·Mar 4, 2019
- NEK7 phosphorylation of cortactin modulates the migratory capacity of cells expressing EML4-ALK V3
Emily L. Richardson, Axel Knebel, … Andrew M. Fry·Scientific ReportsPeer-reviewed·Jan 27, 2026
- Cancer-associated fibroblasts confer ALK inhibitor resistance in EML4-ALK-driven lung cancer via concurrent integrin and MET signaling
Qianqian Hu, Lily L. Remsing Rix, … Uwe Rix·Science SignalingPeer-reviewed·Dec 23, 2025
- Adaptive immunity is required for durable responses to alectinib in murine models of EML4-ALK lung cancer
E. K. Kleczko, T. K. Hinz, … R. A. Nemenoff·bioRxiv·Apr 14, 2022
- The molecular basis of Abelson kinase regulation by its αI-helix
J. Paladini, A. Maier, … S. Grzesiek·bioRxiv·Oct 4, 2023